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Abstract: 
A recombinant bacterial expression system that generates 13C-labeled heme or 15N-labeled heme 
in functional cytochrome P450 enzymes and other heme-containing systems is reported here 
using a mutant strain of Escherichia coli (HU227) in which the HemA gene is inactive. By 
synthesizing several isotopomers of aminolevulinic acid with 13C or 15N at different locations, 
isotopes have been incorporated with high abundance into the heme cofactor of five different 
cytochrome P450 isoforms, along with one peroxidase. Confirmed both 13C- and 15N-
incorporation; spectral and catalytic assays show the labeled enzymes produced in this system 
are functional. 
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The ability to generate hemoprotein samples in which specific positions on the cofactor have 
been isotopically labeled has found utility in recent studies. Paramagnetic NMR and resonance 
Raman spectroscopy are two techniques that have taken advantage of this ability, as shown by 
Alontaga et al. (2006), Caignan et al. (2003) and Balakrishnan et al. (2009). Strategies for 
labeling the heme cofactor with 13C at specific positions have been developed for several 
hemoprotein systems, based on the well-characterized heme biosynthetic pathway shown in Fig. 
1, which is employed by most bacteria, including E. coli. For example, by controlling growth 
conditions and expression of outer membrane (OM) cytochrome b5 in E. coli, in the presence of 
13C-labeled aminolevulinic acid (a biosynthetic heme precursor), efficient labeling of the 
prosthetic group (>85%) at specific locations has been achieved (Rivera and Walker 1995). An 
alternative approach was used by Behr et al. (1998) in which the HemA gene coding for 5-
aminolevulinate synthase (the gene responsible for synthesis of aminolevulinic acid (ALA) in the 
cell) was deleted from a strain of Paracoccus denitrificans, and the media was supplemented with 
13C-labeled aminolevulinic acid. Both of these approaches are useful in specific situations, but 
have limitations, such as the need for reconstitution. 
 
Fig. 1: The biosynthetic pathway of heme starting from [4-13C] aminolevulinic acid. The labeled 
atom represents 13C. In E. coli, aminolevulinic acid is produced via the C-5 pathway starting 
with glutamate. The HemA gene product is a glutamyl-tRNA reductase, which catalyzes the rate-
limiting step in aminolevulinic acid synthesis 
Cytochrome P450s are very difficult to reconstitute, apparently due to the thiolate ligation. 
Although methods have been reported (Wagner et al. 1981), these protocols generally require 
very harsh treatment of the enzyme, which may or may not have adverse irreversible effects on 
the reconstituted sample. Additionally, certain P450 enzymes (and other heme proteins) have 
covalently bound heme cofactors (LeBrun et al. 2002), which precludes the use of techniques 
involving reconstitution. Woodward et al. (2007) developed an E. coli system in which modified 
hemes may be incorporated through media supplementation, however aminolevulinic acid cannot 
be used as a source of heme precursor, as the inactive gene product in this strain is downstream 
from ALA synthesis in the biosynthetic pathway (Rivera and Caignan 2004). In addition, 
cultures must be grown anaerobically, which necessitates the use of more sophisticated culture 
facilities. Our objective was to develop a simple more universal method for efficient 
incorporation of 13C or 15N into the heme cofactor of any heme containing enzyme that can be 
expressed in E. coli, using a variant strain of E. coli (HU227) that cannot produce the heme 
precursor aminolevulinic acid (Li et al. 2003). 
Materials and methods 
Materials 
[4-13C]-Aminolevulinic acid, [1-13C]-, [2-13C]- and 15N-glycine, were from Cambridge Isotope 
Laboratories as a standard. Subsequently, 15N-, [4-13C] and [5-13C]-aminolevulinic acid were 
synthesized according to the method of Wang and Scott (1997) with minor variations, as 
described below. Plasmids for bacterial expression of P4502E1 (Δ3-29), P4502B4 (Δ2-27), 
P450BM3, P450BM3-F87G, dehaloperoxidase (DHP) were obtained from Dr. Jud Coon [The 
University of Michigan, P4502E1(Δ3-29), P4502B4(Δ2-27)], Dr. David Mullen (Tulane 
University, P450BM3, P450BM3-F87G) and Dr John Dawson (The University of South Carolina, 
DHP). CYP102A2 was cloned and expressed in our lab according to the method of Gustafsson et 
al. (2004). The E. coli strain HU227 (F-, hemA41, relA1, spoT1, metB1, rrnB-
2, mcrB1, creC510, Hem-p) was provided by Dr. Jeremy LaLean and cultures of this strain were 
initially grown out in LB media in the presence of a minimum of 10–20 mg aminolevulinic acid 
per liter. 
Synthesis of 13C- and 15N-aminolevulinic acid 
The procedure used is modified slightly from that of Wang and Scott (1997) and is summarized 
in Fig. 2. The mole values, reaction yields and NMR data given in this section, are for reagents 
and products in the synthesis of [5-13C]ALA, however the same procedure was used for 
generation of [4-13C] and 15N-ALA as well. [2-13C]Glycine (99 atom.% 13C, 1.010 g, 
13.28 mmol) was fused with phthalic anhydride (1.992 g, 13.45 mmol) under argon. The 
resulting off-white solid was re-crystallized from water, yielding [2-13C] phthalylglycine as white 
needles (2.470 g, 90.2%); 1H-NMR (DMSO-d6) δ: 4.28 (d, 2H), 7.88 (m, 4H). 
 
Fig. 2 
Synthesis scheme for the preparation of isotopically labeled aminolevulinic acid 
Dried, [2-13C]phthalylglycine (2.388 g, 11.58 mmol) was refluxed for 18 h in thionyl chloride 
(12 l, 165.2 mmol) under argon at 80°C. Thionyl chloride was removed with a rotory evaporator 
leaving [2-13C]phthalimidoacetyl chloride as a yellow powder (2.557 g, 98.3%); 1H-NMR 
(CDCl3) δ: 4.82 (d, 2H), 7.85 (m, 4H). The acid chloride was stored at room temperature for up 
to 2 weeks. 
To produce zinc homoenolate, zinc chloride (2.046 g, 15 mmol) was fused under vacuum and 
dissolved in dry diethyl ether (30 ml). Once a clear homogenous mixture was obtained, dry [(1-
ethoxycyclopropyl)-oxy]trimethylsilane (6 ml, 30 mmol) was added to the reaction drop wise 
with a syringe over 5-min to give a cloudy solution. Stirring continued at room temperature for 
1 h followed by refluxing in a hot oil bath for 30 min. Tetrakis(triphenylphosphine)palladium(0) 
(148 mg, 0.128 mmol) and [2-13C]phthalimidoacetyl chloride (2.413 g, 10.7 mmol) were added 
to the stirring solution on ice. Once a homogenous mixture was obtained,N,N-dimethylacetamide 
(3 ml, 32 mmol) was added slowly via syringe and allowed to stir at 0°C under argon for 1 h 
followed by 2 h at room temperature. The solution was washed with water:dichloromethane (1:2 
v/v) and the organic layer was collected and washed with saturated NaCl. The clear orange 
solution was evaporated under vacuum and [5-13C]phthalimdolevulinic acid ethyl ester was re-
crystallized from ethanol (2.706 g, 90.5%); 1H-NMR (CDCl3) δ: 1.25 (t, 3H), 2.65 (t, 2H), 2.84 
(t, 2H), 4.14 (q, 2H), 4.55 (d, 2H), 7.80 (m, 4H). 
[5-13C]Phthalimidolevulinic acid ethyl ester (2.662 g, 9.57 mmol) was refluxed overnight in 
hydrochloric acid:acetic acid (1:1 v/v) at 120°C. The resulting deep yellow solution was 
evaporated and the residue washed with water to remove excess acid and subsequently with ethyl 
acetate to remove phthalic acid. The aqueous fraction was concentrated under vacuum, and the 
aminolevulinic acid (ALA) was re-crystallized from ethanol and diethyl ether. (1.506 g, 
93.3%) 1H-NMR (D2O) δ: 2.53 (t, 2H), 2.73 (t, 2H), 3.95 (d, 2H). Isotopomers of ALA were 
stored separately at −20°C in brown glass vials. The overall yield was 67%. 
Cell growth and enzyme expression 
Escherichia coli HU227 cells were made competent using CaCl2 treatment and batches were 
transformed using 1 ng of each plasmid described above using standard transformation protocols. 
All P450 isoforms were grown in TB media containing 0.02 g 13C-ALA/l at room temperature 
and induced after 24–48 h growth using 0.3 g IPTG/l. DHP cultures were grown in LB media 
containing 0.02 g 13C-ALA/l at 37°C overnight and induced by addition of 0.15 g IPTG/l. After 
induction, all cell cultures were grown for an additional 24 h at room temperature. To monitor 
cytochrome P4502E1 (Δ3-29) and P4502B4 (Δ2-27) activities, an auxiliary enzyme, NADPH 
cytochrome P450-reductase was also required. A plasmid containing the cDNA encoding the rat 
enzyme was acquired from Dr. Charles Kasper, University of Wisconsin and used to 
transform E. coliBL-21. This enzyme was expressed according to published procedures (Porter et 
al. 1987). 
Protein purifications 
Purifications of P450BM3, P450BM3-F87G and DHP were carried out according to published 
protocols (Raner et al. 2002 and Osborne et al. 2006). For the two mammalian P450s, 2B4(Δ2-
27) and 2E1(Δ3-29), and the NADPH P450 reductase, enzymes were not purified to 
homogeneity, rather crude E. coli membrane samples were prepared via cell lysis, centrifugation 
to remove the cytosol, and re-suspension of 0.5 g cell membranes in 2 ml 100 mM phosphate 
buffer (pH 7.4) containing 0.1 mM EDTA and 15% (v/v) glycerol. 
Assays for P450BM3, P450BM3-F87G, P4502B4(Δ2-27), P4502E1 (Δ3-29), CYP102A2 and DHP 
catalytic activity 
Cytochrome P450BM3 and P450BM3-F87G activities were monitored with p-nitrophenoxy 
dodecanoic acid as substrate as described in the literature Schwaneberg et al. (1999) using a 
Varian Cary 100 Bio UV–visible spectrophotometer. This compound was synthesized according 
to the published protocol. For P4502E1(Δ3-29) and P4502B4(Δ2-27) assay, 10 μl reductase 
membranes and 10 μl P450 membranes were initially combined and pre-incubated for 5 min at 
37°C. Additional reaction components, including the substrate p-nitrophenol and NADPH, were 
then added and the product nitrocatechol was monitored by HPLC as described by Larson et al. 
(1991). For P4502E1(Δ3-29) and P4502B4(Δ2-27), 50 μM p-nitrophenol was used. Product 
analysis was performed on a Shimadzu LC 20A Series HPLC system consisting of an SPD-20A 
UV/Vis detector, LC 20AT solvent delivery, and a Sil 20A autosampler, all controlled using the 
Shimadzu EZStart version 7.3 SP1 software package. DHP activity was measured as described 
(Osborne et al. 2004) except the column was at 20°C rather than 4°C. 
Mass spectral analysis 
 
Samples of isotopically labeled heme were obtained individually from purified samples of DHP. 
Initially, 20 μl of 100 μM purified DHP sample was added to 180 μl acetonitrile (containing 
0.5% acetic acid). The sample was centrifuged and the supernatant subjected to HPLC analysis 
on a 150 × 4.6 cm C18 column (Stellar Phases Inc., Longhorne PA). The eluent was monitored at 
398 nm. The mobile phase used was acetonitrile:water (3:2 v/v) with 0.5% acetic acid at 1 
ml/min. The largest peak, eluting between 8 and 10 min, was collected. Samples were 
lyophilized and frozen at −20°C. Dry heme samples were diluted to 100 μl with methanol and 
used to make 1:10 and 1:100 dilutions in methanol for spotting. The matrix used was a saturated 
solution of α-cyano-4-hydroxycinnamic acid in acetonitrile with 0.1% trifluoroacetic acid. 
Spotting solutions were prepared by adding 1 μl sample to 12 μl matrix diluent, and finally 12 μl 
matrix solution was added. A MALDI plate was spotted with 0.5 μl of this sample for analysis 
on an Applied Biosystems 4700 Proteomics Analyzer in reflector positive mode. 
LC–MS analysis of purified heme isotopomers 
 
Dried heme samples that had been HPLC purified were taken up in 200 μl HPLC mobile phase. 
Samples were centrifuged and injected onto a HPLC equipped with a 5 cm Prevail C-18 column 
(Alltech). MS analysis was performed on an LCQ Advantage Thermo Finnigan coupled LC–MS 
with electrospray ionization. The mass range analyzed was from 350 to 800 Da, and the flow rate 
used during analysis was 0.2 ml/min. 
Results and discussion 
 
Expression of recombinant heme proteins in E. coli Hu227 
 
Standard protocols for making E. coli HU227 cells competent using 100 mM CaCl2, resulted in 
inconsistent transformations, often yielding no transformants. By eliminating the snap-freezing 
in DMSO prior to addition of plasmid DNA, the transformations became more consistent, 
routinely producing >50 transformants from 100 μl competent cells with 1 ng plasmid. 
Following overnight growth at room temperature and induction using 0.3 g IPTG/l, expression of 
cytochrome P450 enzyme was monitored in the whole cells using absorption difference 
spectrophotometry. Figure 3 shows a typical ferrous vs ferrous-Co difference spectrum for the 
whole cells expressing CYP102A2 in the HU227 system. An ε450 value of 9.1 × 10−5 μM−1 
cm−1 was used to approximate the yield of cytochrome P450 in the culture (Gustafsson et al. 
2004). From this culture we estimated a P450 yield of ~250 mM. Table 1 shows the maximum 
yield of different cytochrome P450 isoforms obtained. All of the cytochrome P450 constructs 
examined produced yields in the 70–250 nM range. All of the BM3 plasmid constructs used were 
T7-based yet expression of the P450 gene was still significant, albeit lower than in the lac-based 
systems. The DHP was very efficiently expressed in HU227, yielding nearly 800 nM on a 
consistent basis. Here, the ε406 used to calculate DHP concentration was 193,000 μM−1 cm−1 
(Roach et al. 1997). 
 
Fig. 3 
Reduced versus reduced-CO electronic difference spectrum for expressed cytochrome 
P450102A2 in whole E. coli HU227 cells following IPTG induction. The cells were grown in TB 
media containing 20 mg [5-13C] ALA/l 
Table 1 
Summary of the expression levels, enzymatic activity and the isotopes incorporated, along with 
the observed change in m/Z, for each of the Heme-containing enzymes produced. 
Heme protein Maximum expression Activity Isotopes 
Dehaloperoxidase 850 nmoles/l 
Trichlorophenol-






BM3 200 nmoles/l 
p-Nitrophenoxy dodecanoic 






BM3-F87G 150 nmoles/l 
p-Nitrophenoxy dodecanoic 




102A2 250 nmoles/l 
p-Nitrophenoxy dodecanoic 















aActivities were reported per mg of crude E. coli membranes 
Mass spectral analysis of heme cofactor 
The metabolic pathway for heme biosynthesis from ALA in microorganisms is well understood 
and, based on this knowledge, it was expected that the labeling pattern in the heme cofactor of 
DHP and P450 would follow the pattern shown in Fig. 4. Both enzymes were expressed in the 
presence of three isotopomers of ALA ([4-13C]-, [5-13C]- and 15N-ALA) in HU227 cells, and the 
proteins were purified to homogeneity. The heme cofactor was extracted and purified by HPLC 
and subjected to both electrospray ionization and MALDI Mass spectrometry. Figure 5 a is the 
MALDI mass spectrum acquired for a sample of native heme obtained from a commercial source 
(Sigma-Aldrich). The observed mass for this sample was 616.2 m/Z as expected. This spectrum 
was used for comparison with the heme samples obtained from the recombinant enzymes. All of 
the heme samples derived from 13C-labeled ALA ([4-13C]-ALA and [5-13C]-ALA) displayed a 
major peak at 624.2 m/Z. Figure 5b shows the MALDI-MS for the DHP heme produced from the 
[5-13C]ALA. The mass of 624 is consistent with the predicted mass for these isotopomers, since 
it is expected that a total of eight 13C atoms would be incorporated. The mass of heme 
synthesized from [15N]ALA is shown in Fig. 5c. The major peak at 620.2 m/Z is also consistent 
with the expected mass for this isotopomer, and suggests that four 15N atoms were successfully 
incorporated into the heme. There were also two additional major peaks observed in each of the 
MALDI spectra obtained on the isotopically labeled samples at 590 and 634 m/Z. These two 
additional peaks were of identical mass in each sample, and therefore do not appear to be related 
to the heme itself, but rather impurities from the heme purification, as they are absent in the 
native heme sample. Identical results were obtained using the electrospray ionization technique 




Expected labeling pattern for the different heme groups based on the use of different 
aminolevulinic acid isotopomers and known heme biosynthetic pathway in E. coli 
 
Fig. 5 
MALDI mass spectra for (a) native heme (b) heme extracted from dehaloperoxidase grown and 
expressed in the presence of [5-13C] ALA and (c) heme extracted from dehaloperoxidase grown 
and expressed in the presence of 15N-ALA 
Functional characterization of labeled enzymes 
That the expressed proteins in E. coli HU227 were in their native state was determined using 
standard activity assays for each P450 enzyme. Table 1 summarizes the results of these activity 
assays. For example, P450BM3 wild-type and F87G were active in the de-alkylation of p-
nitrophenoxy dodecanoic acid, with rates of 134 ± 14 and 235 ± 8 min−1, respectively, using 
saturating concentrations of substrate. These values are consistent with published kcat values of 
120 min−1 for the wild-type and our unpublished data with F87G indicating a kcat of 
233 ± 38 min−1 when purified from E. coli BL-21 (DE-3). CYP102A2 activity was also 
measured using p-nitrophenoxydodecanoic acid as a substrate. Here a rate of 9.3 min−1 was 
observed compared with 4.3 min−1 when this enzyme was expressed in E. coli HB101. In the 
case of P450s 2B4 and 2E1, assays were carried out in the presence of the rat NADPH-
cytochrome P450 reductase, which was also expressed in E. coli. For these two isoforms, rates of 
catalysis shown in Table 1 were estimated by measuring p-nitrophenol oxidation in crude E. 
coli membranes containing both the P450 and cytochrome P450 reductase. All five P450 
isoforms were active in their respective assays, demonstrating the functional properties of the 
isotopically labeled enzymes. 
Given that reconstitution methods involving cytochrome P450 enzymes are very tedious and are 
carried out under harsh conditions (Wagner et al. 1981), this method represents a simple and 
effective means to produce active cytochrome P450 enzymes that would be useful for selective 
isotopic labeling studies. It can also be adapted for use with different classes of heme proteins, as 
illustrated using DHP. Recombinant DHP produced in HU227 supplemented with 5-13C-ALA 
catalyzed the dechlorination of trichlorophenol at a rate of 282 ± 20 min−1. This value is higher 
than the value of 198 min−1 reported by Osborne et al. (2004), however their studies were carried 
out at 4°C whereas in the current study, a temperature of 20°C was used. 
In summary, the current study has demonstrated the utility of the HU227 E. coli strain in the 
potential large scale production cytochrome P450 samples with highly enriched heme cofactor. 
The system generates substantial quantities of functional cytochrome P450 enzymes that can be 
labeled at specific C- and N-positions in the heme. The method appears to be universally 
functional with all P450s tested, and does not suffer from the limitations associated with 
reconstitution, thus it should prove to be an effective tool in the preparation of samples for use 
with a variety of spectroscopic methods. 
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